These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19265718)

  • 21. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective risk of cancer in CDKN2A germline mutation carriers.
    Goldstein AM; Struewing JP; Fraser MC; Smith MW; Tucker MA
    J Med Genet; 2004 Jun; 41(6):421-4. PubMed ID: 15173226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.
    Lerman C; Hughes C; Lemon SJ; Main D; Snyder C; Durham C; Narod S; Lynch HT
    J Clin Oncol; 1998 May; 16(5):1650-4. PubMed ID: 9586874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
    Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
    BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hereditary melanoma and predictive genetic testing: why not?
    Riedijk SR; de Snoo FA; van Dijk S; Bergman W; van Haeringen A; Silberg S; van Elderen TM; Tibben A
    Psychooncology; 2005 Sep; 14(9):738-45. PubMed ID: 15744786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later.
    Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1687-97. PubMed ID: 23950214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A testing threshold in a high-risk Australian melanoma cohort: number of primaries, family history and young age of onset impact risk.
    McMeniman EK; Peach E; Lee KJ; Yanes T; Jagirdar K; Stark MS; Soyer HP; Duffy DL; McInerney-Leo AM; Sturm RA
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):e797-e798. PubMed ID: 32386439
    [No Abstract]   [Full Text] [Related]  

  • 29. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
    Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
    J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention.
    Fan M; Pfeffer SR; Lynch HT; Cassidy P; Leachman S; Pfeffer LM; Kopelovich L
    Oncotarget; 2013 Jan; 4(1):128-41. PubMed ID: 23371019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
    Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
    J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CM-Score: a validated scoring system to predict
    Potjer TP; Helgadottir H; Leenheer M; van der Stoep N; Gruis NA; Höiom V; Olsson H; van Doorn R; Vasen HFA; van Asperen CJ; Dekkers OM; Hes FJ;
    J Med Genet; 2018 Oct; 55(10):661-668. PubMed ID: 29661971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.
    Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ
    Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
    Chaudru V; Chompret A; Bressac-de Paillerets B; Spatz A; Avril MF; Demenais F
    J Natl Cancer Inst; 2004 May; 96(10):785-95. PubMed ID: 15150307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic counseling in melanoma.
    Badenas C; Aguilera P; Puig-Butillé JA; Carrera C; Malvehy J; Puig S
    Dermatol Ther; 2012; 25(5):397-402. PubMed ID: 23046018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    Maheu C; Bouhnik AD; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Fricker JP; Caron O; Luporsi E; Gladieff L; Julian-Reynier C
    Psychooncology; 2014 Apr; 23(4):420-7. PubMed ID: 24127257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
    Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
    Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.